The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
The FDA determined that the data presented in a 2022 color additive petition show that this ingredient causes cancer in male laboratory rats exposed to high levels of FD&C Red No. 3 because of a hormonal mechanism that occurs in male rats
The project is set to attract significant manufacturing investments of approximately Rs. 10,500 crore and is also projected to create around 1 lakh direct and indirect jobs
Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A
MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
This facility is considered to be in a minimally acceptable state of compliance with regard to current GMP
Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
Subscribe To Our Newsletter & Stay Updated
